CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.


HER2-Specific CAR T Cells Induce Early Efficacy Without Dose-Limiting Toxicities in Pediatric CNS Tumors

July 21st 2021

Repetitive locoregional infusion of HER2-specific CAR T cells did not induce any dose-limiting toxicities.

Dr. Ghia on Key Findings From the CAPTIVATE Trial in CLL

July 19th 2021

Paolo Ghia, MD, PhD, discusses key findings from the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Sperling on Future Research With CAR T-Cell Therapy in Multiple Myeloma

July 14th 2021

Adam Sperling, MD, PhD, discusses future research with CAR T-cell therapy in multiple myeloma.

Dr. Sperling on Managing CAR T-Cell Therapy–Related Toxicities in Multiple Myeloma

July 9th 2021

Adam Sperling, MD, PhD, discusses managing CAR T-cell therapy–related toxicities in multiple myeloma.

Ide-Cel Granted Positive EU Opinion for Relapsed/Refractory Multiple Myeloma

June 25th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that idecabtagene vicleucel receive conditional marketing authorization for use in adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and a CD38-targeted antibody, and have progressed on their last therapy.

Oncolytic Virus/CAR T-Cell Therapy Combo Shows Preclinical Potential in Solid Tumors

June 19th 2021

City of Hope has entered into a licensing agreement with Imugene Ltd. for the patents covering a combination immunotherapy that enables CD19-directed CAR T-cell therapies to target and eradicate difficult-to-treat solid tumors.

Dr. Epperla on the Efficacy of Brexucabtagene Autoleucel in MCL

June 16th 2021

Narendranath Epperla, MD, MS, discusses the efficacy of brexucabtagene autoleucel in patients with mantle cell lymphoma.

Axi-cel Elicits Durable Response in Relapsed/Refractory FL

June 16th 2021

Henry Chi Hang Fung, MD, discusses how the durable response of axi-cel fills an unmet need for this patient population and the potentially exciting future of the therapy.

Second-Line Liso-cel Demonstrates Significant Benefit Over SOC in Relapsed/Refractory LBCL

June 10th 2021

Lisocabtagene maraleucel demonstrated a highly significant improvement in event-free survival, complete response rate, and progression-free survival over standard of care in the second-line treatment of patients with relapsed/refractory large B-cell lymphoma, meeting primary and secondary end points of the phase 3 TRANSFORM trial.

C-CAR066 Achieves High Marks in Relapsed/Refractory B-NHL

June 8th 2021

C-CAR066 exhibited a favorable safety profile and promising efficacy in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed with prior CD19 CAR T-cell therapy.

Cilta-Cel Demonstrates Durable Responses at 18 Months in Relapsed/Refractory Multiple Myeloma

June 8th 2021

Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

CART-ddBCMA Elicits 100% ORR in Relapsed/Refractory Multiple Myeloma

June 6th 2021

The autologous CAR T-cell product CART-ddBCMA was found to elicit a 100% objective response rate in patients with relapsed/refractory multiple myeloma, with deep and durable responses noted in those with poor prognostic factors.

Brexucabtagene Autoleucel Induces High, Durable Responses in Heavily Pretreated Relapsed/Refractory B-ALL

June 5th 2021

A single infusion of brexucabtagene autoleucel, a CAR T-cell therapy, demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Ide-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma

June 4th 2021

The CAR T-cell therapy idecabtagene vicleucel continues to demonstrate improved survival among heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr. Ghosh on the Role of Off-the-Shelf CAR T-Cell Therapy in Myeloma

June 3rd 2021

Monalisa Ghosh, MD, discusses the role of off-the-shelf CAR T-cell therapy in patients with multiple myeloma.

CAR T-Cell Therapy Trial in Solid Tumors Halted Following 2 Patient Deaths

June 3rd 2021

Tmunity Therapeutics, a clinical-stage biotherapeutics company, has halted the development of its lead CAR T-cell product following the deaths of 2 patients who were enrolled to a trial investigating its use in solid tumors.

FDA Grants Priority Review to Cilta-Cel for Relapsed/Refractory Multiple Myeloma

May 27th 2021

The FDA has granted priority review to the biologics license application for ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma.

FDA Grants Fast Track Status to CAR T-Cell Product AIC100 for Thyroid Cancer

May 19th 2021

The FDA has granted a fast track designation to the CAR T-cell product AIC100 for the treatment of patients with anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.

NKT Cells Co-Expressing GD2-CAR, IL-15 Can Induce Complete Remissions in Pediatric Neuroblastoma

May 15th 2021

Natural killer T cells that co-express GD2-CAR and interleukin-15 were found to be safe and to demonstrate evidence of in vivo expansion and localization to metastatic sites in patients with stage IV relapsed/refractory neuroblastoma.

Liso-cel Expands CAR T-Cell Options in Lymphoma

May 14th 2021

Amitkumar Mehta, MD, the safety profile of liso-cel and how it is advancing the relapsed/refractory large B-cell lymphoma treatment paradigm.